Tuesday, September 1, 2026

Arena Pharmaceuticals Stock Bullish Momentum With A 2.53% Rise On Thursday

ViaNews Editorial Team

December 10, 2020

Arena Pharmaceuticals Stock Bullish Momentum With A 2.53% Rise On Thursday
The Nasdaq Stock Market ended the session with Arena Pharmaceuticals jumping 2.53% to $70.62 on Thursday, following yesterday's downward trend. The Nasdaq Stock Market rose 0.54% to $12,405.80, following yesterday's downward trend on what was a somewhat positive trend exchanging session today. Arena Pharmaceuticals today's close was $70.62, 27.71% under its 52-week high of $90.19.

Arena Pharmaceuticals's Sales

Arena Pharmaceuticals's sales growth is a negative 81.3% for the present quarter and 155.7% for the next. The company's growth estimates for the ongoing quarter is a negative 4.5% and positive 4.5% for the next.

Arena Pharmaceuticals's Revenue

Year-on-year quarterly revenue growth declined by 98.5%, now sitting on 3.28M for the twelve trailing months.

Arena Pharmaceuticals's Stock Top and Bottom Yearly Value

Arena Pharmaceuticals's stock is valued at $70.62 at 17:35 EST, way below its 52-week high of $90.19 and way above its 52-week low of $32.95.

Arena Pharmaceuticals's Moving Average

Arena Pharmaceuticals's value is under its 50-day moving average of $73.43 and higher than its 200-day moving average of $69.02.
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge: Late-August 2026 Funding Wave Spans Fintech, Enterprise Agents, and Robotics
A dense cluster of funding rounds landing on 2026-08-28 — from identity/fraud fintech player Socure ($156M plus its acquisition of Fravity) to enterprise AI agent startups (Instinct, Generalist AI, Owner), model infrastructure (Stability AI, Emerald AI), and autonomous logistics/aerospace (Gatik, Regent Craft) — signals investors are rotating aggressively into AI-native companies with demonstrable ROI, especially in financial risk/compliance and back-office automation. Parallel signals (Multiverse Computing's compression benchmarks cutting inference cost/latency, and Arkestro/CloneOps.ai publishing hard savings and labor-displacement figures) suggest the funding is chasing efficiency and measurable economic impact rather than pure model scale.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,980
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,980 facts checked against source5,267 source documents archived
Query this data → isubstrate.com